36 related articles for article (PubMed ID: 18157578)
1. Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.
Guadagni S; Clementi M; Bencivenga M; Kusamura S; Fiorentini C; Masedu F
Updates Surg; 2018 Dec; 70(4):441-447. PubMed ID: 30191532
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques.
Guadagni S; Fiorentini G; Clementi M; Palumbo P; Mambrini A; Masedu F
Updates Surg; 2017 Sep; 69(3):403-410. PubMed ID: 28791628
[TBL] [Abstract][Full Text] [Related]
3. The negative-balance isolated pelvic perfusion method using ultrahigh-dose cisplatin for invasive bladder cancer with poor risk.
Kimata R; Kondo Y; Nemoto K; Murata S; Kumazaki T
Int J Clin Oncol; 2010 Oct; 15(5):433-9. PubMed ID: 20405154
[TBL] [Abstract][Full Text] [Related]
4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
5. Pelvic perfusion for locally recurrent unresectable rectal tumors.
Unal AE; Bayar S; Tez M; Gocmen E; Kocaoglu H; Akgul H
Hepatogastroenterology; 2005; 52(63):757-60. PubMed ID: 15966199
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer.
Motoyama S; Hamana S; Ku Y; Laoag-Fernandez JB; Deguchi M; Yoshida S; Tominaga M; Iwasaki T; Ohara N; Maruo T
Gynecol Oncol; 2004 Dec; 95(3):576-82. PubMed ID: 15581966
[TBL] [Abstract][Full Text] [Related]
7. Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience.
Jurado M; Alcázar JL; Martinez-Monge R
Gynecol Oncol; 2010 Jan; 116(1):38-43. PubMed ID: 19878978
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
9. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Wanebo HJ; DiSiena M; Begossi G; Belliveau J; Gustafson E
Ann Surg Oncol; 2008 Apr; 15(4):1107-16. PubMed ID: 18157578
[TBL] [Abstract][Full Text] [Related]
10. Pelvic perfusion for advanced colorectal cancers.
Begossi G; Belliveau JF; Wanebo HJ
Surg Oncol Clin N Am; 2008 Oct; 17(4):825-42, ix-x. PubMed ID: 18722921
[TBL] [Abstract][Full Text] [Related]
11. [Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept].
Horváth Ors P; Papp A; Kalmár K; Cseke L; Yousuf AF; Esik O
Magy Seb; 2006 Oct; 59(5):333-41. PubMed ID: 17201341
[TBL] [Abstract][Full Text] [Related]
12. [Pelvic perfusion for localy advanced tumors].
Bonvalot S; Muret J; Debaere T
Bull Cancer; 2009 Jan; 96(1):103-9. PubMed ID: 19211365
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
